| Title |
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|
|---|---|
| Published in |
New England Journal of Medicine, September 2019
|
| DOI | 10.1056/nejmoa1910836 |
| Pubmed ID | |
| Authors |
James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, Jean-Jacques Grob, Piotr Rutkowski, Christopher D Lao, C Lance Cowey, Dirk Schadendorf, John Wagstaff, Reinhard Dummer, Pier F Ferrucci, Michael Smylie, David Hogg, Andrew Hill, Ivan Márquez-Rodas, John Haanen, Massimo Guidoboni, Michele Maio, Patrick Schöffski, Matteo S Carlino, Céleste Lebbé, Grant McArthur, Paolo A Ascierto, Gregory A Daniels, Georgina V Long, Lars Bastholt, Jasmine I Rizzo, Agnes Balogh, Andriy Moshyk, F Stephen Hodi, Jedd D Wolchok |
X Demographics
The data shown below were collected from the profiles of 695 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 175 | 25% |
| United Kingdom | 41 | 6% |
| Spain | 39 | 6% |
| Canada | 18 | 3% |
| Australia | 16 | 2% |
| Turkey | 12 | 2% |
| Brazil | 11 | 2% |
| France | 11 | 2% |
| Germany | 8 | 1% |
| Other | 109 | 16% |
| Unknown | 255 | 37% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 426 | 61% |
| Practitioners (doctors, other healthcare professionals) | 132 | 19% |
| Scientists | 122 | 18% |
| Science communicators (journalists, bloggers, editors) | 15 | 2% |
Mendeley readers
The data shown below were compiled from readership statistics for 1,736 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1736 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 202 | 12% |
| Student > Ph. D. Student | 195 | 11% |
| Student > Bachelor | 159 | 9% |
| Other | 145 | 8% |
| Student > Master | 131 | 8% |
| Other | 253 | 15% |
| Unknown | 651 | 38% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 447 | 26% |
| Biochemistry, Genetics and Molecular Biology | 222 | 13% |
| Immunology and Microbiology | 101 | 6% |
| Agricultural and Biological Sciences | 69 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 56 | 3% |
| Other | 152 | 9% |
| Unknown | 689 | 40% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1880. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 April 2024.
All research outputs
#5,248
of 25,738,558 outputs
Outputs from New England Journal of Medicine
#301
of 32,659 outputs
Outputs of similar age
#74
of 360,022 outputs
Outputs of similar age from New England Journal of Medicine
#4
of 244 outputs
Altmetric has tracked 25,738,558 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 32,659 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 122.7. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 360,022 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 244 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.